Jazz Pharmaceuticals plc
Price Action
Technical Summary
STAGE 2 UPTRENDJazz Pharmaceuticals plc is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 86), indicating clear outperformance against the broad market. Earnings growth of 391% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $232.38 | -2.78% | BELOW |
| 50 SMA | $220.81 | +2.31% | ABOVE |
| 100 SMA | $199.95 | +12.99% | ABOVE |
| 150 SMA | $189.50 | +19.22% | ABOVE |
| 200 SMA | $175.52 | +28.72% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is JAZZ in an uptrend right now?
JAZZ has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, JAZZ is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is JAZZ overbought or oversold?
JAZZ's RSI (14) is 46. The stock is in neutral territory, neither overbought nor oversold.
Is JAZZ outperforming the market?
JAZZ has a Relative Strength (RS) Rating of 86 out of 99. Yes, JAZZ is a market leader, outperforming 86% of all stocks over the past 12 months.
Where is JAZZ in its 52-week range?
JAZZ is trading at $225.92, which is 93% of its 52-week high ($243.32) and 87% above its 52-week low ($105.00).
How volatile is JAZZ?
JAZZ has a Beta of 0.46 and 52-week volatility of 37%. It's less volatile than the S&P 500 - generally more stable.